Northwest Georgia Oncology Centers

Marietta, Georgia 30060

2 studies enrolling now · 21 studies all time

What they study most

B-cell Lymphoma, Biliary Tract Cancer (BTC), Breast Cancer, Carcinoma of Unknown Primary, Colorectal Cancer (CRC), Diffuse Large B-cell Lymphoma, Endometrial Cancer, Extensive-stage Small Cell Lung Cancer, Gastroesophageal Cancer (GC), HER-2 Positive Breast Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

Studies at this site

• Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Avelumab Program Rollover Study — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Completed
• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors — Completed
• Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) — Running, not enrolling
• Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer — Completed
• KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer — Stopped early
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer — Stopped early
• Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma — Completed
• A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma — Stopped early
• A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) — Completed
• Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer — Stopped early
• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary — Completed
• Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer — Completed
• Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) — Completed
• Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma — Stopped early
• Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) — Stopped early
• A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Stopped early